Oral vs Injectable Testosterone on GLP-1: Which Form Works?

Three oral testosterone products are now FDA-approved in the United States — Jatenzo (Clarus), Kyzatrex (Marius), and Tlando (Lipocine), all twice-daily oral testosterone undecanoate formulations that absorb through the intestinal lymphatics and require dietary fat. The food-effect data is unambiguous: Yin 2012 in the Journal of Andrology^[1] showed serum testosterone AUC falls roughly 60–80% when oral testosterone undecanoate is taken without a fat-containing meal. Semaglutide and tirzepatide both delay gastric emptying (Hjerpsted 2018^[4], Schneck & Urva 2024^[5]), and the GLP-1 systematic review by Calvarysky 2024 in Drug Safety^[6] flagged oral-absorption interactions as the dominant DDI class. The practical implication: on a GLP-1, the predictable choice is injectable cypionate or a transdermal gel — both bypass the GI tract and side-step the entire interaction.

The honest summary

• Oral testosterone undecanoate needs dietary fat. Yin 2012^[1] dose-ranged dietary fat from 0 to ~50 g and showed serum T AUC scales steeply with fat content; the FDA labels for Jatenzo, Kyzatrex, and Tlando all require twice-daily dosing with food. Without enough fat, oral T is unreliable even in steady-state.
• GLP-1 delays gastric emptying. Hjerpsted 2018^[4] measured semaglutide vs placebo in adults with obesity and showed the first-hour gastric emptying rate is slowed roughly 30%. Tirzepatide population PK (Schneck & Urva 2024^[5]) is consistent with a longer and more variable gastric-residence time, which is the mechanism behind tirzepatide’s nausea profile.
• Calvarysky 2024 flagged the oral interaction. The systematic review^[6] reviewed published GLP-1 DDI studies and identified delayed and variable absorption of oral medications — especially fat-soluble products and narrow-therapeutic-index drugs — as the dominant DDI mechanism. Oral T undecanoate sits squarely in the fat-soluble, food-effect-dependent category.
• Injectable cypionate is the clean alternative. IM testosterone cypionate or enanthate, dosed 100–200 mg weekly, bypasses the gut entirely. The TRAVERSE trial (Lincoff 2023 NEJM^[7]) randomized 5,246 hypogonadal men to transdermal T vs placebo over 22 months and reported no excess in major adverse cardiovascular events (HR 0.96, 95% CI 0.78–1.17) — the strongest CV-safety dataset we have for any TRT route.

How oral testosterone undecanoate actually works

Testosterone has dreadful oral bioavailability if it goes through the portal system — first-pass hepatic metabolism destroys most of it before it reaches the systemic circulation, which is why injectable and transdermal formulations dominated the market for decades. Jatenzo, Kyzatrex, and Tlando solve this by formulating testosterone undecanoate (a fatty-acid ester of testosterone) in a self-emulsifying lipid matrix. When dosed with a fat-containing meal, the drug is preferentially absorbed into intestinal lymph via chylomicrons rather than the portal vein, bypassing first-pass hepatic metabolism.

Yin 2012^[1] ran the formal food-effect pharmacokinetic study in hypogonadal men. The trial dosed the same oral TU product after meals containing 0 g, 15 g, 30 g, and 50 g of fat. Serum testosterone AUC scaled steeply with dietary fat across the range, and the difference between a no-fat condition and a moderate-fat (~30 g) meal was on the order of 60–80% of total exposure. The FDA labels for all three approved oral TU products (Jatenzo, Kyzatrex, Tlando) translate that into a twice-daily-with-food dosing instruction. The Swerdloff 2020 JCEM pivotal trial^[2] for Jatenzo and the DelConte 2022 Andrology trial^[3] for Tlando both enrolled patients on a controlled fed protocol; the real-world signal is that adherence to the with-food rule is the dominant predictor of whether serum T reaches the eugonadal range.

The three FDA-approved oral products at a glance

• Jatenzo (Clarus Therapeutics). Oral testosterone undecanoate 158, 198, and 237 mg capsules. Dosed twice daily with food. Approved 2019 on the basis of the Swerdloff 2020 JCEM trial^[2]. Requires a formal dose-titration protocol with serum T re-measurement ~7 hours after the morning dose.
• Kyzatrex (Marius Pharma). Oral testosterone undecanoate 100, 150, and 200 mg capsules. Dosed twice daily with food. Approved 2022.
• Tlando (Lipocine). Oral testosterone undecanoate 112.5 mg capsules. Dosed twice daily with food. Approved 2022. The DelConte 2022 Andrology trial^[3] reported that the fixed 225 mg twice-daily regimen eliminates the dose-titration step that Jatenzo requires.

All three products share the same fundamental constraint: without a fat-containing meal at each dosing event, serum T falls below the eugonadal range in a meaningful fraction of patients. This is a feature of the lymphatic-absorption mechanism, not a formulation defect.

What GLP-1 therapy does to gastric emptying

Hjerpsted 2018^[4] measured gastric emptying in adults with obesity randomized to semaglutide 1.0 mg weekly vs placebo for 12 weeks, using a paracetamol-absorption test as the index of first-hour gastric emptying. Semaglutide significantly reduced the first-hour gastric emptying rate, with the largest effect immediately after dose initiation and partial tachyphylaxis by week 12. Population PK modeling of tirzepatide (Schneck & Urva 2024^[5]) is consistent with substantial slowing of GI transit, which is the mechanistic basis of tirzepatide’s well-documented nausea profile in SURMOUNT-1.

The Calvarysky 2024 Drug Safety systematic review^[6] aggregated the published GLP-1 DDI literature across more than 40 oral co-medications and reached the same conclusion the FDA prescribing information now warns about: GLP-1 receptor agonists slow and de-synchronize the absorption of oral drugs, with the largest effect on lipophilic, food-dependent formulations and on drugs with narrow therapeutic windows. The review explicitly noted oral hormonal products as a class where the food-effect interaction warrants attention.

Why oral T on a GLP-1 is unpredictable

Oral testosterone undecanoate has two pharmacologic features that compound when stacked with a GLP-1:

1. It requires dietary fat at the dosing event. The label dose is twice daily with food. GLP-1 therapy suppresses appetite and frequently reduces meal-fat content — patients on Wegovy or Zepbound often eat smaller, lower-fat meals, especially after dose escalation. A breakfast of plain Greek yogurt or a protein shake does not deliver the 15–30 g of fat that the oral TU labels assume.
2. Its absorption is gut-transit-time-sensitive. Lymphatic absorption depends on chylomicron formation in the small intestine. Slowed gastric emptying delays and prolongs the gastric-emptying-into-duodenum step, shifting the absorption window. There is no published PK study of oral TU on a GLP-1 specifically, but the Calvarysky systematic review^[6] identifies this class as a high-likelihood interaction.

The clinical signal we expect, based on the mechanism: greater between-patient variability in steady-state serum T, more frequent below-range troughs, and a higher need for dose adjustment after each GLP-1 escalation. Patients who do achieve a stable T level on oral TU before starting a GLP-1 should plan for re-measurement of total testosterone roughly 4 weeks after each GLP-1 dose increase.

Magnitude: predictable testosterone exposure by route

The injectable alternative: cypionate, enanthate, undecanoate

Injectable testosterone bypasses the GI tract entirely. The TRAVERSE trial (Lincoff 2023 NEJM^[7]) is the largest cardiovascular safety dataset for any TRT route: 5,246 hypogonadal men with cardiovascular risk factors randomized to transdermal testosterone vs placebo, with a median 22 months of follow-up. The primary MACE endpoint hazard ratio was 0.96 (95% CI 0.78–1.17), establishing non-inferiority for the transdermal route. Injectable cypionate and enanthate share the same systemic-exposure profile once steady-state is reached and have decades of clinical use behind them.

• Testosterone cypionate (Depo-Testosterone). IM injection, typical dose 100–200 mg weekly or 50–100 mg twice weekly. Half-life ~8 days. The dominant DTC and clinic-prescribed protocol. GoodRx cash pricing is approximately $30/month at Costco for generic cypionate.
• Testosterone enanthate. IM injection, typical dose 100–200 mg weekly. Half-life ~5 days. Functionally interchangeable with cypionate at equivalent doses.
• Testosterone undecanoate (Aveed). IM injection every 10 weeks after a 4-week loading dose. Long half-life, requires in-office administration in the United States because of a labeled risk of post-injection anaphylaxis and pulmonary oil microembolism. Cash cost is higher (~$200/month equivalent) and access is restricted to REMS-certified prescribers.

The transdermal alternative

Transdermal testosterone (AndroGel, Testim, Fortesta, Vogelxo) also bypasses the gut. Daily application, steady-state serum T in the eugonadal range for most patients. The dominant limitation is the transfer risk: skin-to-skin contact can transfer measurable testosterone to women and children, and the labels carry boxed warnings on that risk. Patients living with young children or in close contact with a pregnant partner usually prefer the injectable route for that reason. Generic AndroGel pump pricing is roughly $50–100/month cash on GoodRx.

The practical decision tree

1. Starting both TRT and a GLP-1 at the same time → injectable cypionate or transdermal gel. The oral route adds a second variable on top of the GLP-1 dose escalation and is not the right choice for a patient with no baseline steady-state T data.
2. Already stable on oral TU, starting a GLP-1 → monitor. Total testosterone at week 4 after each GLP-1 dose escalation, plus a single mid-titration measurement. Switch to injectable if serum T trends below the eugonadal range or if the patient is no longer consistently eating fat-containing meals at oral TU dosing times.
3. Already stable on injectable or transdermal T, starting a GLP-1 → no change. The route is inherently insulated from the GLP-1 effect. Standard TRT monitoring (hematocrit, PSA, estradiol at 3, 6, 12 months) continues unchanged.
4. Needle phobia is the patient’s dominant objection → transdermal first, oral second. Transdermal is the clean non-injectable option on a GLP-1. Oral TU remains an option if the patient is committed to eating a fat-containing meal at each dose and to more frequent monitoring.

What the costs look like

• Testosterone cypionate IM (generic): ~$30/month cash via GoodRx at Costco; ~$60–100/month through DTC telehealth platforms that bundle clinician fees.
• Testosterone enanthate IM (generic): ~$35/month cash.
• Aveed IM (testosterone undecanoate): ~$200/month equivalent plus in-office administration cost.
• Jatenzo oral: ~$200/month cash; commercial insurance variable, often requires prior authorization.
• Kyzatrex oral: ~$200/month cash; manufacturer coupons available.
• Tlando oral: ~$200/month cash.
• Generic AndroGel pump: ~$50–100/month cash via GoodRx.
• DTC concierge stacks (Hone-class): ~$200–250/month all-in including labs and clinician visits.

Related research

• TRT and GLP-1 stacking — the combined-therapy protocol, monitoring cadence, and what TRAVERSE plus SURMOUNT data imply for the stack.
• Best TRT clinics 2026 — ranked cash-pay DTC TRT telehealth on diagnostic rigor, formulary breadth, and monitoring.
• GLP-1 and erectile dysfunction — how weight-loss-driven T normalization changes the calculus on who actually needs TRT.
• TRT and weight loss — the published body-composition data for testosterone replacement in hypogonadal men.

Important disclaimer. This article is educational and does not constitute medical advice. Testosterone replacement therapy carries class-specific risks (erythrocytosis, prostate effects, fertility suppression, possible thrombotic risk) and route-specific risks (injection site reactions for IM, transfer risk for transdermal, anaphylaxis risk for Aveed, hepatotoxicity surveillance for all oral testosterone undecanoate products per their prescribing information). Patients with untreated prostate cancer, untreated severe OSA, active fertility plans, recent unprovoked VTE, or hematocrit above 54% should not start TRT without a specialist evaluation. PMIDs were verified live against the PubMed E-utilities API on 2026-05-28; FDA-label details were verified against the current DailyMed monographs for Jatenzo, Kyzatrex, Tlando, Depo-Testosterone, Aveed, and AndroGel.

Last verified: 2026-05-28. Next review: every 12 months, or sooner if a head-to-head PK study of oral testosterone undecanoate on semaglutide or tirzepatide is published.